Editas Medicine, Inc. Common Stock (EDIT) is a publicly traded Healthcare sector company. As of July 5, 2026, EDIT trades at $3.65 with a market cap of $560.14M and a P/E ratio of -3.12. EDIT moved +10.98% today. Year to date, EDIT is +78.92%; over the trailing twelve months it is +42.58%. Its 52-week range spans $0.91 to $4.54. Analyst consensus is buy with an average price target of $7.20. Rallies surfaces EDIT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Editas Medicine Launches $125M Share Offering After 90% LDL Reduction in Primates: Cowen & Co reiterated its Buy rating for Editas Medicine after data showing a single dose of EDIT-401 reduced LDL-cholesterol by approximately 90% in non-human primate models. The company launched a 55.5 million share offering with $2.25-priced warrant units to raise $125 million, with potential $194.4 million more upon full exercise.
| Metric | Value |
|---|---|
| Price | $3.65 |
| Market Cap | $560.14M |
| P/E Ratio | -3.12 |
| EPS | $-1.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.54 |
| 52-Week Low | $0.91 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $38.69M |
| Net Income | $-108.95M |
| Gross Margin | 0.00% |
7 analysts cover EDIT: 0 strong buy, 5 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.20.